Launched in 2013, Therapeutics Alliances facilitates the translation of academic biomedical research conducted at NYU into successful industry partnerships focused on developing new therapeutics.
Our success is built on the legacies of blockbuster drugs such as Remicade and Sutent, which were based on licensed NYU Langone research and have helped treat more than 1 million people.
About Therapeutics Alliances
Therapeutics Alliances is a unique and comprehensive drug accelerator that operates like a “virtual biotechnology company” to identify and de-risk select NYU projects and enable greater dealmaking with investors and biopharmaceutical companies.
We provide a variety of resources involving target discovery and validation, assay development, hit finding, and hit-to-lead optimization for small molecules, biologics, and other modalities. In addition to funding, we bring together a dedicated internal staff of project managers and analysts as well as experienced external biopharmaceutical consultants, including medicinal chemists, in vitro pharmacologists, biologics experts, peptide chemists, and more.
Therapeutics Alliances utilizes many world-class contract research organizations that specialize in drug discovery services such as high-throughput screening, virtual screening, biologics, medicinal chemistry, biochemical assays, drug metabolism and pharmacokinetics, and more.
All our projects receive resources customized to meet the specific scientific and business needs required to secure a quality partnership with biopharmaceutical companies and investors. We seamlessly align each project’s scientific work with related business development and intellectual property efforts to maximize the likelihood of completing successful deals.
Request for Proposals
Details for the next request for proposals will be posted later this year.